Cargando…

Ploidy Testing of Blastocoel Fluid for Screening May Be Technically Challenging and More Invasive Than That of Spent Cell Culture Media

BACKGROUND: Recent studies have demonstrated that both blastocoel fluid (BF) and spent cell culture media (SCM) have potential as materials for non-invasive or less-invasive pre-implantation genetic analysis. BF may allow more opportunity to obtain cell-free DNA from the inner cell mass (ICM), and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Wenhao, Zhao, Zhenghao, Xue, Xia, Li, Qian, Yao, Yaxin, Wang, Dongyang, Wang, Jing, Lu, Sijia, Shi, Juanzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900197/
https://www.ncbi.nlm.nih.gov/pubmed/35264976
http://dx.doi.org/10.3389/fphys.2022.794210
Descripción
Sumario:BACKGROUND: Recent studies have demonstrated that both blastocoel fluid (BF) and spent cell culture media (SCM) have potential as materials for non-invasive or less-invasive pre-implantation genetic analysis. BF may allow more opportunity to obtain cell-free DNA from the inner cell mass (ICM), and it has a lower risk of containing contaminant DNA from cumulus cells, sperm and culture media. There are no data regarding the ICM as a gold standard to evaluate the chromosome constitution of BF or SCM for embryo liquid biopsy. METHODS: Two hundred eighteen donated human blastocysts were warmed and cultured in blastocyst culture media for 18–24 h. The corresponding SCM was collected, and only clear ICM was biopsied in blastocysts; otherwise, the whole blastocyst (WB) was biopsied. Quantitative PCR was performed to determine the DNA levels in the SCM and BF before and after amplification. ChromInst was used to amplify BF/SCM and blastocyst DNA before sequencing. Chromosomal copy number variation (CNV) was investigated to evaluate the chromosome constitution. RESULTS: In total, 212 blastocysts were available for SCM and BF collection. The technical success rates (next-generation sequencing data) were 100 and 69.8% (148/212) for SCM and BF, respectively. Among the 148 blastocysts with both SCM and BF data, 101 were euploid and 47 were aneuploid based on ICM (n = 89) or WB (n = 59) analysis as the gold standard. Among all blastocysts, SCM was comparable to BF [specificity: 80.2 versus 61.4% (P = 0.005, χ(2) test); sensitivity: 91.5 versus 87.2% (P = 0.738, χ(2) test); negative predictive value (NPV): 95.3 versus 91.2% (P = 0.487, χ(2) test); positive predictive value (PPV): 68.3% versus 51.3% (P = 0.042, χ(2) test)]. The SCM and BF samples were 83.8% (124/148) and 69.6% (103/148) concordant with the corresponding ICM/WB samples when only two categories, euploid or aneuploid/mosaic, were grouped to calculate the concordance. CONCLUSIONS: Compared with BF, SCM has superior diagnostic performance, and it is non-invasive for embryos. CLINICAL TRIAL REGISTRATION: [http://www.chictr.org.cn], identifier [ChiCTR-BPD-17014087].